Literature DB >> 15001817

Modulation of drug transporters at the blood-brain barrier.

Gert Fricker1, David S Miller.   

Abstract

A major challenge in the management of diseases of the central nervous system is the limited penetration of drugs into the brain. The structures responsible are the capillaries of the brain, whose endothelial cells form the so-called blood-brain barrier. Understanding the cellular and molecular structure as well as integrated function of this barrier is a prerequisite for successful drug delivery to the brain. Here we briefly review current knowledge about the active transport proteins (ABC and organic anion transporters) which function at the blood-brain barrier. We describe novel approaches to (1). modulate carrier protein function, and (2). circumvent the transporter-based carrier by targeted site-specific drug delivery systems, such as immunoliposome and nanoparticulate systems. Copyright 2004 S. Karger AG, Basel

Mesh:

Substances:

Year:  2004        PMID: 15001817     DOI: 10.1159/000075545

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  19 in total

Review 1.  Blood-brain barrier: structural components and function under physiologic and pathologic conditions.

Authors:  Yuri Persidsky; Servio H Ramirez; James Haorah; Georgette D Kanmogne
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-06       Impact factor: 4.147

2.  Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

Authors:  Martina Hubensack; Christine Müller; Peter Höcherl; Stephan Fellner; Thilo Spruss; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-12       Impact factor: 4.553

Review 3.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

Review 4.  Cellular elements of the blood-brain barrier.

Authors:  Jorge Correale; Andrés Villa
Journal:  Neurochem Res       Date:  2009-10-25       Impact factor: 3.996

5.  Tumor necrosis factor alpha increases P-glycoprotein expression in a BME-UV in vitro model of mammary epithelial cells.

Authors:  Mohammad M Al-Bataineh; Deon van der Merwe; Bruce D Schultz; Ronette Gehring
Journal:  Biopharm Drug Dispos       Date:  2010-10-22       Impact factor: 1.627

Review 6.  Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.

Authors:  C Ballatore; K R Brunden; J Q Trojanowski; V M-Y Lee; A B Smith; D M Huryn
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

7.  Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.

Authors:  Sonja Eberl; Bertold Renner; Antje Neubert; Mareike Reisig; Iouri Bachmakov; Jörg König; Frank Dörje; Thomas E Mürdter; Andreas Ackermann; Harald Dormann; Karl G Gassmann; Eckhart G Hahn; Stefanie Zierhut; Kay Brune; Martin F Fromm
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  In situ blood-brain barrier permeability of a C-10 paclitaxel carbamate.

Authors:  Carlo Ballatore; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  Bioorg Med Chem Lett       Date:  2008-10-10       Impact factor: 2.823

9.  Nociceptive inhibition prevents inflammatory pain induced changes in the blood-brain barrier.

Authors:  Christopher R Campos; Scott M Ocheltree; Sharon Hom; Richard D Egleton; Thomas P Davis
Journal:  Brain Res       Date:  2008-05-17       Impact factor: 3.252

Review 10.  Multiple Molecular Mechanisms to Overcome Multidrug Resistance in Cancer by Natural Secondary Metabolites.

Authors:  Mahmoud Zaki El-Readi; Ahmed M Al-Abd; Mohammad A Althubiti; Riyad A Almaimani; Hiba Saeed Al-Amoodi; Mohamed Lotfy Ashour; Michael Wink; Safaa Yehia Eid
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.